What Is Sickle Cell Disease? A Comprehensive Overview

Understanding Sickle Cell Disease

Sickle cell disease (SCD) is a group of inherited red blood cell disorders that affects millions of people worldwide. In healthy individuals, red blood cells are round and flexible, allowing them to travel easily through blood vessels to deliver oxygen throughout the body. In people with SCD, a mutation in the hemoglobin gene causes red blood cells to become rigid and shaped like a crescent or sickle, particularly under conditions of low oxygen, dehydration, or physiological stress.

This seemingly simple change in cell shape has devastating consequences. Sickled cells are sticky and inflexible, causing them to clump together and block small blood vessels. These blockages — called vaso-occlusive crises — reduce blood flow and oxygen delivery to tissues and organs, leading to episodes of extreme pain, organ damage, and a range of serious complications that affect virtually every organ system.

The Genetics of Sickle Cell Disease

SCD is caused by a point mutation in the HBB gene on chromosome 11, which encodes the beta-globin subunit of hemoglobin. Specifically, a single nucleotide change (GAG to GTG) at the sixth codon results in the amino acid valine being substituted for glutamic acid. This produces an abnormal form of hemoglobin known as hemoglobin S (HbS).

SCD follows an autosomal recessive inheritance pattern. A person must inherit two copies of the sickle cell gene — one from each parent — to develop the disease. When both parents carry the sickle cell trait (HbAS), each pregnancy carries a 25% chance of producing a child with SCD (HbSS), a 50% chance of producing a carrier (HbAS), and a 25% chance of producing a child with normal hemoglobin (HbAA).

The sickle cell trait (HbAS) is notably prevalent in regions where malaria is endemic because carriers have a natural resistance to severe malaria — an evolutionary advantage known as the heterozygote advantage or balanced polymorphism. This explains why SCD is most common in sub-Saharan Africa, where malaria has been a major selective pressure for thousands of years.

Symptoms and Complications

The clinical manifestations of SCD are wide-ranging and can vary significantly from person to person. Common symptoms and complications include:

• Chronic anemia: Sickled red blood cells break down prematurely (hemolysis), living only 10 to 20 days compared to the normal 120-day lifespan. This chronic destruction of red blood cells leads to persistent anemia, causing fatigue, weakness, and pallor.
• Pain crises (vaso-occlusive crises): The hallmark of SCD. Episodes of severe pain occur when sickled cells block blood flow in small vessels. Pain can occur in the bones, chest, abdomen, and joints, lasting hours to weeks. These crises are the most common reason for emergency department visits and hospitalizations.
• Acute chest syndrome: A life-threatening complication involving fever, chest pain, and a new infiltrate on chest X-ray. It is the leading cause of death and second most common cause of hospitalization in SCD patients.
• Stroke: Children with SCD have a 200 to 400 times higher risk of stroke compared to the general pediatric population. Approximately 11% of SCD patients will experience a stroke before age 20 without preventive intervention.
• Organ damage: Progressive damage to the spleen, kidneys, liver, lungs, and eyes occurs over time due to repeated vaso-occlusion and chronic hemolysis. Splenic sequestration can be fatal in young children.
• Increased infection risk: Functional asplenia (loss of spleen function) develops early in childhood, making patients highly susceptible to infections from encapsulated bacteria such as Streptococcus pneumoniae and Haemophilus influenzae.

Global Prevalence

SCD is one of the most common genetic disorders in the world. International health bodies estimate that more than 300,000 babies are born with sickle cell disease each year, and that number is projected to increase to over 400,000 by 2050 due to population growth in high-prevalence regions.

Sub-Saharan Africa bears the overwhelming burden, accounting for approximately 75% of all SCD births globally. Nigeria alone accounts for roughly 150,000 SCD births per year, making it the country with the highest burden of sickle cell disease in the world. Other high-prevalence countries include the Democratic Republic of Congo, Tanzania, India, and several West African nations where the sickle cell trait prevalence can reach 20-30% of the population.

Treatment and Management

While there is currently no widely available cure for SCD, several treatment strategies can significantly improve quality of life and survival:

• Hydroxyurea: The most important disease-modifying therapy for SCD. Hydroxyurea increases the production of fetal hemoglobin (HbF), which inhibits the polymerization of HbS and reduces sickling. Clinical trials have demonstrated that hydroxyurea reduces pain crises by 44%, acute chest syndrome episodes by 50%, and the need for blood transfusions by approximately 50%. It is recommended for all patients aged 9 months and older with HbSS or HbSB0 thalassemia.
• Blood transfusions: Chronic transfusion therapy reduces stroke risk by 90% in high-risk children identified through transcranial Doppler screening. Simple and exchange transfusions are also used to treat acute complications.
• Bone marrow transplantation (BMT): Currently the only established curative therapy for SCD. Matched sibling donor transplants have a cure rate exceeding 90%, but donor availability, cost, and transplant-related complications limit its use, particularly in low-resource settings.
• Gene therapy: Emerging gene-based therapies, including gene addition and gene editing approaches using CRISPR-Cas9, represent promising avenues for cure. Several clinical trials have shown encouraging results, though accessibility and cost remain significant barriers.
• Supportive care: Penicillin prophylaxis, immunizations, folic acid supplementation, adequate hydration, and regular comprehensive care visits form the foundation of SCD management.

Life Expectancy and the Importance of Early Diagnosis

In high-income countries with comprehensive SCD programs, median survival has improved dramatically — reaching 50 to 60 years in the United States and parts of Europe. However, in sub-Saharan Africa, where most SCD patients live, an estimated 50 to 80% of affected children die before their fifth birthday, largely due to late diagnosis, limited access to preventive care, and inadequate treatment of acute complications.

Early diagnosis through newborn screening is critical. When SCD is identified at birth, lifesaving interventions — including penicillin prophylaxis, vaccination, parental education, and enrollment in comprehensive care programs — can be initiated immediately. Studies from the United States and Jamaica have demonstrated that newborn screening programs reduce under-5 mortality from SCD by more than 70%.

This is precisely why platforms like Tracka exist: to ensure that every child born with sickle cell disease in Africa is identified early, enrolled in care, and tracked throughout their lifetime to maximize their chances of a healthy, productive life.